Tetradecylthioacetic acid

CAS No. 2921-20-2

Tetradecylthioacetic acid( —— )

Catalog No. M28915 CAS No. 2921-20-2

Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
5MG 37 In Stock
10MG 61 In Stock
25MG 107 In Stock
50MG 166 In Stock
100MG 259 In Stock
200MG 389 In Stock
500MG 634 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tetradecylthioacetic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.
  • Description
    Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.(In Vivo):Mice receiving HFD supplemented with 0.75% (w/w) TTA had significantly lower body weights compared to mice fed the diet without TTA. Plasma triacylglycerol (TAG) was reduced 3-fold with TTA treatment, concurrent with increase in liver TAG. Total cholesterol was unchanged in plasma and liver. However, TTA promoted a shift in the plasma lipoprotein fractions with an increase in larger HDL particles. Histological analysis of the small intestine revealed a reduced size of lipid droplets in enterocytes of TTA treated mice, accompanied by increased mRNA expression of fatty acid transporter genes. Expression of the cholesterol efflux pump Abca1 was induced in the small intestine, but not in the liver. Scd1 displayed markedly increased mRNA and protein expression in the intestine of the TTA group.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2921-20-2
  • Formula Weight
    288.49
  • Molecular Formula
    C16H32O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 2 mg/mL (6.93 mM)
  • SMILES
    CCCCCCCCCCCCCCSCC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.EUBULUS BIOTHERAPEUTICS - WO2021/183702, 2021, A1.
molnova catalog
related products
  • GFT505

    GFT505 (Elafibranor) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.

  • Bocidelpar

    Bocidelpar is a modulator of PPARδ with an EC50 of 7.80 nM and improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy muscle cells.

  • JW55

    JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.